Paris (ots/PRNewswire) - - EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus(R)- - Topline results of EDITION II consistent with EDITION I findings - Sanofi announced today that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with ...
2014 International Summit of Cooperatives
Quebec City (ots/PRNewswire) - Food security, access to health care and health services, the global job crisis and cooperative development and strengthening The 2014 International Summit of Cooperatives has announced its major program themes. These ambitious, bold themes will garner the attention and interest of cooperatives from every sector of the global economy as ...
Paris (ots/PRNewswire) - Sanofi announced today that clinical data highlighting the company's ongoing commitment to advancing diabetes care will be presented at the American Diabetes Association (ADA) 73rd Scientific Sessions in Chicago, USA (June 21-25, 2013). In total, more than 60 abstracts representing new data ...
Espoo, Finland (ots/PRNewswire) - Finnish diabetes technology company Mendor announces today the CE mark for its groundbreaking diabetes management platform, Mendor Balance(R). This cloud-based platform seeks to introduce significant benefits to all the key stakeholders: patients, health care professionals, payers and the pharma industry. Mendor Balance enables people living with diabetes to effortlessly share their blood ...
Shire Pharmaceuticals Group Plc
Dublin (ots/PRNewswire) - Honor extraordinary carers who sacrifice for others The BRAVE Awards, an international awards initiative that recognizes the courage and dedication of non-professional caregivers, is seeking nominations through June 30, 2013. Developed and implemented by Shire plc, the global biopharmaceutical company, the BRAVE Awards honor unpaid, ...
Bristol-Myers Squibb GmbH & Co. KGaA
Paris (ots/PRNewswire) - AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - Intended only for European media based outside of the UK - 53% response rate observed in patients receiving 1 mg/kg nivolumab plus 3 mg/kg Yervoy concurrently (n= 9 of 17), the dose used in the Phase 3 trial; of these responders all experienced at least 80% tumor shrinkage ...
Shire Pharmaceuticals Group Plc
Philadelphia (ots/PRNewswire) - Shire LLC has settled its litigation against Teva Pharmaceuticals USA Inc. ("Teva") in connection with Teva's Abbreviated New Drug Application ("ANDA") for a generic version of Shire's INTUNIV (guanfacince) Extended Release Tablets for the treatment of Attention Deficit Hyperactivity Disorder. The settlement provides Teva with a license ...
Janssen Infectious Diseases-Diagnostics BVBA
Beerse, Belgium (ots/PRNewswire) - -INCIVO(R) triple therapy now offers a twice daily HCV treatment regimen which should improve patient adherence[1] - Janssen Infectious Diseases-Diagnostics BVBA (Janssen) announced today that the European Commission (EC) has approved a new twice daily (BID) dosing of INCIVO(R) ...
http://resources.euroadhoc.com/us/yY4HmTMz issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard: SIX Swiss ...
Lugano, Switzerland & Copenhagen, Denmark (ots) - The decision follows promising findings from a Phase IIa Proof-of-Concept study. Helsinn is planning a Phase IIb study with elsiglutide, and study activities are expected to start in H2 2013. The Swiss pharmaceutical group Helsinn, a leading player in the cancer ...
http://resources.euroadhoc.com/us/MDjWVqpS issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
London (ots/PRNewswire) - Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy (HE) where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition ...
Aachen (ots) - Healthcare professionals who would like to know more about the topical treatment of postherpetic neuralgia (PHN) can now find useful information online. PHN is a chronic disabling pain condition with symptoms often described as burning, stabbing, or shooting pain, and caused by a previous herpes zoster infection (commonly known as shingles). The new ...
Stockholm (ots/PRNewswire) - Oncopeptides AB, a company working to enhance oncology therapies, today announced the conclusion of a series A financing round intended to fund the phase II program. HealthCap led the investment with support from the long-term investor Industrifonden; members of Oncopeptides' management ...
Munich, Germany (ots) - * Lack of patient adherence to hypertension treatment is one of the root causes of failure to reach blood pressure goals, contributing to increased risk of serious cardiovascular events * The Daiichi Sankyo myHypertensionCare patient support programme aims to improve patient engagement and ...
http://resources.euroadhoc.com/us/yvKBMcrX http://resources.euroadhoc.com/us/VnwXYtUH issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 ...
Hatfield, England (ots/PRNewswire) - New data on early real life experience show perampanel is effective and well tolerated in patients with difficult-to-treat partial epilepsy The antiepileptic drug (AED) Fycompa (perampanel), shows a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy according to the investigators of two new analyses on ...
http://resources.euroadhoc.com/us/e9GCka6w issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, presented positive, statistically significant, top-line results from its VASCAZEN(R)-REVEAL trial for ...
Uithoorn, The Netherlands (ots/PRNewswire) - Starting 1 September 2013, HOYA appointed Mrs. Olga Prenat as the new Dean of HOYA's Faculty Education & Experience Centre in Budapest, Hungary. Currently holding the position of Director of the Institute and Centre of Optometry in Bures sur Yvette - France, Mrs. Prenat follows up Mr. Hans Warntjes who will officially retire in June after having worked with HOYA for 24 years. ...
Woodbridge, Ontario (ots/PRNewswire) - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that Dr. George Jackowski, Founder, Chairman and Chief Scientific Officer was awarded the Queen Elizabeth II Diamond Jubilee Medal ...
http://resources.euroadhoc.com/us/sOfmajm1 issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: ...
Beerse, Belgium (ots/PRNewswire) - - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA ...
Daiichi Sankyo Company (TSE: 4568) and Perosphere Inc
Mount Kisco, New York And Tokyo (ots/PRNewswire) - Daiichi Sankyo to support and co-sponsor phase 1 Clinical Study Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and ...
http://resources.euroadhoc.com/us/00U8dOCD issuer: LifeWatch AG Rundbuckstrasse 6 CH-8212 Neuhausen am Rheinfall phone: +41 52 632 00 50 FAX: +41 52 632 00 51 mail: users@lifewatch.com WWW: www.lifewatch.com sector: Healthcare Providers ISIN: CH0012815459 indexes: SPI, SPIEX stockmarkets: free trade: ...
Bristol-Myers Squibb GmbH & Co. KGaA
Princeton, New Jersey (ots/PRNewswire) - - This all-oral treatment regimen is being studied as an interferon-free and ribavirin-free option - Investigational regimen involves three different classes of direct-acting antivirals (DAAs) - an NS5A replication complex inhibitor, an NS3 protease inhibitor and an NS5B ...
The European Brain Council, Global Alliance of Mental Illness Advocacy Networks-Europe and Shire AG
Brussels (ots/PRNewswire) - A new Expert White Paper, ADHD: Making the Invisible Visible, was today presented to policymakers and key stakeholders by a multidisciplinary group of experts. This Expert White Paper project was initiated, facilitated and funded by Shire AG and supported by the European Brain Council ...
Maidenhead, England (ots/PRNewswire) - Who: ViroPharma, an international biopharmaceutical company committed to developing and commercialising innovative solutions for physicians to address the unmet medical needs of patients living with diseases that have few, if any, clinical therapeutic options. What: European ...
Lyon, France (ots/PRNewswire) - Hexyon is Europe's only fully liquid, ready-to-use hexavalent paediatric vaccine Sanofi Pasteur MSD, the joint venture between MSD and Sanofi Pasteur in Europe, announced today that the European Commission has granted a community marketing authorisation for Hexyon[TM], an innovative new 6-in-1 paediatric vaccine. Hexyon[TM] is the only fully liquid, ready-to-use 6-in-1 vaccine to protect ...